Current role
Kanya Rajangam, M.D., Ph.D.
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Kanya Rajangam, M.D., Ph.D.
Senti Biosciences Holdings, Inc. reported in an 8-K filed May 17, 2024 that Kanya Rajangam, M.D., Ph.D. was appointed President, effective May 14, 2024.
“Kanya Rajangam, M.D., Ph.D., the Company's Head of Research and Development, and Chief Medical Officer, was appointed to serve as the President of the Company, effective as of May 14, 2024, until her successor as President is duly appointed by the Board, or until her earlier death, resignation, retirement, removal or termination of her office as President.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Current
2024-05-14–present
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Senti Biosciences Holdings, Inc.
Other people whose current roles at this company are on record from its filings.
- Timothy Lu CEO, Board Member
- Jay Cross CFO
- Timothy Lu, M.D., Ph.D. CFO, Chief Accounting Officer
- Philip Lee CTO
- Yvonne Li Chief Accounting Officer
- Bryan Baum Board Member
- Feng Hsiung Board Member
- Fran Schulz Board Member
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.